Institut Catala d'Oncologia-L'Hospitalet

L'Hospitalet de Llobregat (bcn) 08907

0 studies enrolling now · 1 studies all time

What they study most

Lymphoma, Non-Hodgkin

Studies at this site

• A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy — Stopped early